Next Article in Journal
When a Neonate Is Born, So Is a Microbiota
Next Article in Special Issue
Spatio-Temporal Expression Pattern of Ki-67, pRB, MMP-9 and Bax in Human Secondary Palate Development
Previous Article in Journal
Pheophorbide a Derivatives Exert Antiwrinkle Effects on UVB-Induced Skin Aging in Human Fibroblasts
Previous Article in Special Issue
The Need for Head Space: Brachycephaly and Cerebrospinal Fluid Disorders
 
 
Communication

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19

1
North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy
2
Division of Pharmacology and Pharmacovigilance, University of Pisa, 56126 Pisa, Italy
3
Unit of Adverse Drug reaction Monitoring, Pisa University Hospital, 56124 Pisa, Italy
4
Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Tissa Wijeratne
Life 2021, 11(2), 144; https://doi.org/10.3390/life11020144
Received: 20 January 2021 / Revised: 1 February 2021 / Accepted: 11 February 2021 / Published: 15 February 2021
(This article belongs to the Special Issue 2020: A 10 Years Journey—Advances in Life Sciences)
Effective treatments specific for COVID-19 are still lacking. In the setting of passive immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of COVID-19 convalescent plasma (CCP) anti-SARS-CoV-2 Spike protein monoclonal antibodies (mAb), which have been granted emergency use authorization, have suggested benefit in early disease course (less than 72 hours from symptoms and seronegative). Meanwhile, polyclonal immunoglobulins (i.e., hyperimmune serum), derived either from CCP donations or from animals immunized with SARS-CoV-2 antigens, are likely to become the next nAb-derived candidate. We here discuss the pros and cons of hyperimmune serum versus CCP and mAb, and summarize the ongoing clinical trials of COVID-19 hyperimmune sera. View Full-Text
Keywords: COVID-19; SARS-CoV-2; polyclonal immunoglobulins; convalescent plasma; Cohn’s fractionation; IgG; passive immunotherapy COVID-19; SARS-CoV-2; polyclonal immunoglobulins; convalescent plasma; Cohn’s fractionation; IgG; passive immunotherapy
MDPI and ACS Style

Focosi, D.; Tuccori, M.; Franchini, M. The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. Life 2021, 11, 144. https://doi.org/10.3390/life11020144

AMA Style

Focosi D, Tuccori M, Franchini M. The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. Life. 2021; 11(2):144. https://doi.org/10.3390/life11020144

Chicago/Turabian Style

Focosi, Daniele, Marco Tuccori, and Massimo Franchini. 2021. "The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19" Life 11, no. 2: 144. https://doi.org/10.3390/life11020144

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop